Business Context and Reporting Period
Company: Herbalife Ltd.
Filing Type: Form 8-K (Current Report)
Date of Report: August 21, 2017
Event: Commencement of a modified "Dutch auction" tender offer to repurchase common shares.
Key Financial Metrics and Offer Terms
- Aggregate Cash Purchase Price: Up to $600 million.
- Per Share Price Range: Not less than $60.00 and not greater than $68.00, net to the seller in cash.
- Additional Consideration: A non-transferable contractual contingent value right (CVR) for potential future payments upon a "Going Private Transaction."
- Maximum Shares Repurchasable:
- At $60.00/share: 10,000,000 shares (approx. 10.64% of outstanding shares as of August 15, 2017).
- At $68.00/share: 8,823,529 shares (approx. 9.39% of outstanding shares as of August 15, 2017).
- Expiration Date: September 19, 2017, at 5:00 p.m. New York City time (subject to extension).
- Financing: The offer is not conditioned upon the receipt of financing.
Material Changes and Conditions
This filing announces a significant capital allocation event rather than a change in operating results. The tender offer is subject to certain conditions, which the Company may waive at its discretion. The final purchase price will be determined after the expiration date based on the lowest price within the specified range that allows the Company to purchase the maximum number of shares for up to $600 million. If the offer is oversubscribed, shares will be purchased on a pro rata basis, with priority given to "odd lots" (less than 100 shares).
Guidance, Outlook, and Management Commentary
- Board Recommendation: The Board of Directors unanimously approved the offer based on the recommendation of an independent committee. However, the Board, Company, and agents are making no recommendation to shareholders regarding whether to tender shares.
- Insider Intent: Directors, executive officers, and Carl C. Icahn and his controlled affiliates do not intend to tender any shares or sell common shares during the offer period.
- Forward-Looking Statements: The filing includes standard disclaimers regarding future expectations, including the sufficiency of cash and credit sources to meet expenditures. It explicitly states that no assurances can be given that a "going private" transaction will be consummated.
- Risks: Risks include potential decreases in public float, reduced liquidity and trading volume, and increased price volatility following the offer. Legal strategies and pending claims are also noted as potential risks.
Important Facts for Investor Verification
- Verify the final "Cash Purchase Price" once determined after the September 19, 2017, expiration date.
- Confirm the total number of shares actually tendered and the pro rata acceptance rate if the offer is oversubscribed.
- Review the terms of the Contingent Value Rights (CVR) Agreement to understand the conditions and timeline for potential future payments.
- Monitor subsequent filings for any updates on the "Going Private Transaction" or changes to the offer terms.
- Check the Company's liquidity position in the most recent 10-Q to assess the impact of the $600 million cash outflow on working capital.